Skip to main content
. 2019 Feb 21;111(11):1216–1227. doi: 10.1093/jnci/djz026

Figure 1.

Figure 1.

Sensitivity of human fetal osteoblasts and osteosarcoma (OS) cell lines to Tegavivint in vitro. A) Nontransformed hFOB1.19 or previously established OS cell lines, or B) patient-derived xenograft (PDX)-derived cell lines were treated with increasing concentrations of Tegavivint for up to 72 hours, and cell viability was assessed via CCK-8 assay. Error bars represent 95% confidence intervals. C) Half-maximal inhibitory concentration (IC50) doses of Tegavivint were calculated based on the results of CCK-8 assay. D) Immunoblot analysis of β-catenin and c-Myc in paired primary and lung metastatic OS cell lines was performed by treating each cell line for 24 hours with the appropriate IC50 dose of Tegavivint. E) Immunoblot analysis of subcellular localization for β-catenin using cell fractions from metastatic LM7 and TCCC-OS84 cells was performed by treating each cell line for 24 hours with the appropriate IC50 dose of Tegavivint.